It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OABI’s FA Score shows that 1 FA rating(s) are green whileSLRN’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OABI’s TA Score shows that 3 TA indicator(s) are bullish while SLRN’s TA Score has 5 bullish TA indicator(s).
OABI (@Biotechnology) experienced а -14.16% price change this week, while SLRN (@Biotechnology) price change was -20.51% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.
OABI is expected to report earnings on May 11, 2023.
SLRN is expected to report earnings on Nov 13, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
OABI | SLRN | OABI / SLRN | |
Capitalization | 470M | 468M | 100% |
EBITDA | -59.55M | -375.08M | 16% |
Gain YTD | -37.115 | -37.131 | 100% |
P/E Ratio | N/A | N/A | - |
Revenue | 21.7M | 0 | - |
Total Cash | 57.2M | 635M | 9% |
Total Debt | 24.3M | 1.07M | 2,273% |
OABI | SLRN | |
---|---|---|
RSI ODDS (%) | 3 days ago42% | 3 days ago82% |
Stochastic ODDS (%) | 3 days ago61% | 3 days ago90% |
Momentum ODDS (%) | 3 days ago58% | 3 days ago89% |
MACD ODDS (%) | 3 days ago62% | 3 days ago90% |
TrendWeek ODDS (%) | 3 days ago67% | 3 days ago86% |
TrendMonth ODDS (%) | 3 days ago74% | 3 days ago90% |
Advances ODDS (%) | 12 days ago64% | 13 days ago79% |
Declines ODDS (%) | 5 days ago84% | 3 days ago90% |
BollingerBands ODDS (%) | 3 days ago43% | 3 days ago78% |
Aroon ODDS (%) | 3 days ago84% | 3 days ago72% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GSAKX | 16.79 | -0.05 | -0.30% |
Goldman Sachs International Eq Inc A | |||
VADCX | 74.40 | -0.56 | -0.75% |
Invesco Equally-Wtd S&P 500 C | |||
EXOSX | 32.28 | -0.40 | -1.22% |
Manning & Napier Overseas Series I | |||
DCFGX | 39.19 | -0.99 | -2.46% |
Dunham Focused Large Cap Growth C | |||
EFCAX | 20.73 | -0.58 | -2.72% |
Emerald Insights A |
A.I.dvisor indicates that over the last year, OABI has been loosely correlated with NTLA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if OABI jumps, then NTLA could also see price increases.
Ticker / NAME | Correlation To OABI | 1D Price Change % | ||
---|---|---|---|---|
OABI | 100% | -4.67% | ||
NTLA - OABI | 48% Loosely correlated | -7.61% | ||
ABCL - OABI | 45% Loosely correlated | -3.99% | ||
FATE - OABI | 45% Loosely correlated | -2.88% | ||
DNLI - OABI | 45% Loosely correlated | -11.95% | ||
AURA - OABI | 45% Loosely correlated | -5.02% | ||
More |
A.I.dvisor indicates that over the last year, SLRN has been loosely correlated with ACLX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if SLRN jumps, then ACLX could also see price increases.
Ticker / NAME | Correlation To SLRN | 1D Price Change % | ||
---|---|---|---|---|
SLRN | 100% | -9.11% | ||
ACLX - SLRN | 39% Loosely correlated | -7.63% | ||
OABI - SLRN | 38% Loosely correlated | -4.67% | ||
CMND - SLRN | 38% Loosely correlated | -8.84% | ||
IDYA - SLRN | 38% Loosely correlated | -9.60% | ||
TRML - SLRN | 38% Loosely correlated | -5.65% | ||
More |